Therapy Directory

Rituximab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention. Browse Rituximab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1303

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Interventions: Cladribine, Laboratory Biomarker Analysis, Rituximab; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mantle Cell Lymphoma
Interventions: Venetoclax Oral Tablet [Venclexta]; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 60 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Sickle Cell
Interventions: Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Mantle Cell Lymphoma
Interventions: Rituximab, Bendamustine, Cytarabine; Drug
Lead sponsor: Christine Ryan; Other
Eligibility: 18 Years to 69 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Interventions: Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 2 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 0 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma, Mantle Cell Lymphoma
Interventions: rituximab, Bendamustine, bortezomib, lenalidomide; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2031
U.S. locations: 416
States / cities: Anchorage, Alaska • Antioch, California • Fremont, California + 283 more

Conditions: Mature B-Cell Lymphoma
Interventions: COPAD, COP, COPD M3, CYM, COP, COPADM8, CYVE; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions: RIC regimen, GVHD prophylaxis regimen; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2033
U.S. locations: 4
States / cities: New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more

Conditions: Lymphoma, Lymphoma, B-Cell
Interventions: Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq; Drug · Device
Lead sponsor: Jennifer Amengual; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Laboratory Biomarker Analysis, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Epcoritamab, Rituximab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

About this Rituximab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Rituximab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Rituximab clinical trials

Filter and sort this therapy

Live official records

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Siplizumab for Sickle Cell Disease Transplant

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Mature B-Cell Lymphoma And Leukemia Study III

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Epcoritamab and Rituximab for First-line Follicular Lymphoma

About this Rituximab clinical trials directory page